Legal & General Group
CCCC icon

Legal & General Group’s C4 Therapeutics CCCC Stock Holding History

Legal & General Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.9K Buy
+9,834
New +$33.6K ﹤0.01% 2788
2025
Q2 		– Sell
-5,063
Closed -$8.07K – 3438
2025
Q1 		$8.07K Hold
5,063
– – ﹤0.01% 3215
2024
Q4 		$18.2K Hold
5,063
– – ﹤0.01% 3053
2024
Q3 		$28.9K Hold
5,063
– – ﹤0.01% 2910
2024
Q2 		$23.3K Buy
+5,063
New +$30.2K ﹤0.01% 2960
2023
Q2 		– Sell
-5,591
Closed -$17.6K – 3429
2023
Q1 		$17.6K Sell
5,591
-7,844
-58% -$46.2K ﹤0.01% 3101
2022
Q4 		$79.3K Buy
13,435
+1,072
+9% +$8.89K ﹤0.01% 2866
2022
Q3 		$109K Buy
12,363
+1,017
+9% +$10.6K ﹤0.01% 2793
2022
Q2 		$86K Buy
11,346
+3,755
+49% +$33K ﹤0.01% 2894
2022
Q1 		$185K Sell
7,591
-24
-0.3% -$583 ﹤0.01% 2699
2021
Q4 		$245K Buy
7,615
+524
+7% +$20.7K ﹤0.01% 2630
2021
Q3 		$317K Buy
7,091
+2,520
+55% +$108K ﹤0.01% 2549
2021
Q2 		$173K Buy
4,571
+3,477
+318% +$125K ﹤0.01% 2576
2021
Q1 		$40K Sell
1,094
-44
-4% -$1.75K ﹤0.01% 2889
2020
Q4 		$38K Buy
+1,138
New +$33K ﹤0.01% 2874

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Legal & General Group's CCCC Position: Q2 2026 in Review

Legal & General Group opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 9,834 shares worth $45.9K. The stake represents ﹤0.01% of the portfolio and ranks #2788 among its holdings. This is a return to the name: Legal & General Group previously reported a position in CCCC as recently as Q1 2025.

Legal & General Group first reported a position in CCCC in Q4 2020 and has held it in 15 quarters since. The position peaked at $317K in Q3 2021. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Legal & General Group held 9,834 shares of C4 Therapeutics worth $45.9K as of Q2 2026.
  • C4 Therapeutics was a new Legal & General Group position in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2788 holding.
  • Legal & General Group first reported a position in C4 Therapeutics in Q4 2020 and has held it in 15 quarters since.
  • Legal & General Group's C4 Therapeutics position peaked at $317K in Q3 2021.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.